MSCMCC gastric cancer cohort: indirect comparison between adjuvant chemoradiation and perioperative chemotherapy in gastric cancer patients in a re...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Mydlowska
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors M. Mydlowska1, Z. Guzel-Szczepiorkowska1, S. Rybski1, J. Krynski2, A. Cencelewicz1, M. Winiarek3, J. Zwolinski2, E. Kosakowska2, T. Olesinski1, L. Wyrwicz1
  • 1M Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland, /
  • 2Department of Gastrointestinal Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, /
  • 3Dept of Gastrointestinal Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, /

Abstract

In the western world gastric cancer patients are either treated with peri-operative chemotherapy or adjuvant chemoradiation. There are no direct comparisons of these two treatment strategies and ongoing studies will not be able to clearly distinguish which strategy gives better oncological outcomes and what subgroups of patients benefit from either of these modalities. In our referral gastric cancer treatment site at Maria Sklodowska-Curie Memorial Cancer Center (MSCMCC) we have changed in January 2013 the treatment strategy from adjuvant chemoradiation (like in INT-0116 study) to peri-operative chemotherapy (ECF or CF regimen). Here we report a single institution indirect comparison of two treatment strategies in the treatment of gastric cancer patients.